Overview A Study to Evaluate the Tolerance and Pharmacokinetics of TQB2858 Injection in Subjects With Terminal Malignant Tumors Status: Recruiting Trial end date: 2025-12-12 Target enrollment: Participant gender: Summary This study is a phase I study to evaluate the safety and tolerability of TQB2858 injection in patients with advanced malignancy. Phase: Phase 1 Details Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.